In patients resistant to BRAF and MEK inhibitors, GRP78 upregulation and ATF4 phosphorylation were found, suggesting that ER translocation of the MAPK pathway causes treatment resistance in BRAF-mutant melanoma (38). This evidence concerns the gene MAP2K7 and melanoma.